These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30633928)

  • 1. Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention.
    Marshall CA; Brodnik ZD; Mortensen OV; Reith MEA; Shumsky JS; Waterhouse BD; España RA; Kortagere S
    Neuropharmacology; 2019 Apr; 148():178-188. PubMed ID: 30633928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease.
    Schneider JS; Marshall CA; Keibel L; Snyder NW; Hill MP; Brotchie JM; Johnston TH; Waterhouse BD; Kortagere S
    Exp Neurol; 2021 Jan; 335():113514. PubMed ID: 33141071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noradrenergic terminals are the primary source of α
    Devoto P; Flore G; Saba P; Scheggi S; Mulas G; Gambarana C; Spiga S; Gessa GL
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():97-103. PubMed ID: 30472147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
    Masana M; Bortolozzi A; Artigas F
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):53-68. PubMed ID: 20701825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.
    Schmeichel BE; Zemlan FP; Berridge CW
    Neuropharmacology; 2013 Jan; 64(1):321-8. PubMed ID: 22796428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
    Simms SL; Huettner DP; Kortagere S
    Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related changes in prefrontal norepinephrine transporter density: The basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats.
    Bradshaw SE; Agster KL; Waterhouse BD; McGaughy JA
    Brain Res; 2016 Jun; 1641(Pt B):245-57. PubMed ID: 26774596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.
    Berridge CW; Devilbiss DM; Andrzejewski ME; Arnsten AF; Kelley AE; Schmeichel B; Hamilton C; Spencer RC
    Biol Psychiatry; 2006 Nov; 60(10):1111-20. PubMed ID: 16806100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.
    Xu W; Wang X; Tocker AM; Huang P; Reith ME; Liu-Chen LY; Smith AB; Kortagere S
    ACS Chem Neurosci; 2017 Mar; 8(3):486-500. PubMed ID: 27801563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD.
    Bari A; Robbins TW
    Psychopharmacology (Berl); 2013 Nov; 230(1):89-111. PubMed ID: 23681165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
    Bymaster FP; Katner JS; Nelson DL; Hemrick-Luecke SK; Threlkeld PG; Heiligenstein JH; Morin SM; Gehlert DR; Perry KW
    Neuropsychopharmacology; 2002 Nov; 27(5):699-711. PubMed ID: 12431845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Administration of Methylphenidate (Ritalin) Affects Dopamine Release Differentially Between the Prefrontal Cortex and Striatum: A Microdialysis Study in the Monkey.
    Kodama T; Kojima T; Honda Y; Hosokawa T; Tsutsui KI; Watanabe M
    J Neurosci; 2017 Mar; 37(9):2387-2394. PubMed ID: 28154152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased dopamine transporter function as a mechanism for dopamine hypoactivity in the adult infralimbic medial prefrontal cortex following adolescent social stress.
    Novick AM; Forster GL; Hassell JE; Davies DR; Scholl JL; Renner KJ; Watt MJ
    Neuropharmacology; 2015 Oct; 97():194-200. PubMed ID: 26056032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex.
    Pan WH; Yang SY; Lin SK
    Synapse; 2004 Jul; 53(1):44-52. PubMed ID: 15150740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder.
    Viggiano D; Ruocco LA; Arcieri S; Sadile AG
    Neural Plast; 2004; 11(1-2):133-49. PubMed ID: 15303310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.
    Bymaster FP; Golembiowska K; Kowalska M; Choi YK; Tarazi FI
    Synapse; 2012 Jun; 66(6):522-32. PubMed ID: 22298359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex.
    Xing B; Li YC; Gao WJ
    Brain Res; 2016 Jun; 1641(Pt B):217-33. PubMed ID: 26790349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.
    Somkuwar SS; Kantak KM; Dwoskin LP
    J Neurosci Methods; 2015 Aug; 252():55-63. PubMed ID: 25680322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys.
    Seu E; Lang A; Rivera RJ; Jentsch JD
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):505-19. PubMed ID: 18604598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.